Ivermectin Tops Metronidazole for Papulopustular Rosacea

This article originally appeared here.
Share this content:
Ivermectin Tops Metronidazole for Papulopustular Rosacea
Ivermectin Tops Metronidazole for Papulopustular Rosacea

(HealthDay News) -- For patients with papulopustular rosacea (PPR), once-daily ivermectin 1 percent cream (IVM 1 percent) is superior to twice-daily metronidazole (MTZ 0.75 percent) cream, according to a study published in the April issue of the British Journal of Dermatology.

Alain Taieb, M.D., Ph.D., from Hôpital Saint-André in Bordeaux, France, and colleagues conducted a phase 3 randomized trial involving patients with PPR. Participants were randomized to receive once-daily IVM 1 percent cream (478 participants) or twice-daily MTZ 0.75 percent cream (484 participants) for 16 weeks. Inflammatory lesion counts and Investigator's Global Assessment (IGA) were used to assess efficacy.

The researchers found that IVM 1 percent was significantly superior to MTZ 0.75 percent at week 16 in terms of reduction in inflammatory lesions from baseline (83.0 versus 73.7 percent; P < 0.001). This superiority was observed as early as week three. IVM 1 percent was also superior in terms of IGA results (subjects 'clear' or 'almost clear') (84.9 versus 75.4 percent; P < 0.001). Comparable adverse event incidence was seen between the groups; local tolerability was superior for IVM 1 percent. Global improvement was rated as 'excellent' or 'good' by more patients receiving IVM.

"In conclusion, while MTZ 0.75 percent cream has been the standard treatment for the papulopustular lesions of rosacea, its efficacy is now surpassed by that of IVM along with the advantage of once-daily dosing and high patient satisfaction," the authors write.

Two authors disclosed financial ties to Galderma R&D, which manufactures ivermectin and funded the study.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »